Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study
Cancer Immunology, Immunotherapy · 17.07.2026 · 75 (11)
DOI: 10.1007/s00262-026-04466-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 17.07.2026. Verfasst von Vincenzo De Falco und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, Via Sergio Pansini 5, 80131, Naples, Italy. vincenzo.defalc…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immunotherapy. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi della Campania Luigi Vanvitelli.
Abstract (Originalsprache)
Background
Cutaneous melanoma (CM) is an aggressive cancer since early stages. Stage IIB/C CM present significant recurrence risk. Recently, adjuvant immunotherapy demonstrated to increase recurrence-free survival (RFS) in this setting.
Objective
Assess safety and efficacy of adjuvant immunotherapy for stage IIB/C CM in a real-world setting.
Methods
Stage IIB/C CM patients treated with adjuvant immunotherapy in eight centers from the “Gruppo Oncologico Italia Meridionale” (GOIM) were retrospectively investigated. Data were collected over a median follow-up of 16 months.
Results
Ninety-six patients with a median age of 59 years were included. Most participants were male (64.6%). Approximately 60.4% were classified stage IIB and 39.6% stage IIC, with the majority of tumors localized on the trunk (54.2%). Toxicity occurred in 63.5% of patients with 79.7% of these events classified as grade 1–2 (CTCAE v5.0). The most reported events were thyroid dysfunction, fatigue, gastrointestinal disorders and itchiness. Recurrence was observed only in 7 patients (7.3%).
Conclusions
The 12-month and 24-month RFS were respectively 98.7% and 82.6%. The toxicity profile was generally manageable in a real-life population, however 17.6% of all patients experienced grade 3–4 AEs, underscoring the importance of evaluating adjuvant therapy in a multidisciplinary setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, Via Sergio Pansini 5, 80131, Naples, Italy. vincenzo.defalco2@unicampania.it.
- Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, Via Sergio Pansini 5, 80131, Naples, Italy.
- Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.
- Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- Istituto Tumori IRCCS Giovanni Paolo II, Bari, Italy.
- Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Förderung
- Università degli Studi della Campania Luigi Vanvitelli
Zitieren
APA
De Falco, V., Colloca, A., Argenziano, G., Scala, M., Guida, M., Ottaviano, M., Sergi, M. C., Santarpia, M., Del Giudice, T., Grimaldi, A. M., Cozzolino, S., Forte, M., Caraglia, F., Cioli, E., Esposito, A., Giugliano, M. C., Sparano, F., Iovino, F., Tolone, S., …, & Troiani, T. (2026). Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04466-0
Vancouver
De Falco V, Colloca A, Argenziano G, Scala M, Guida M, Ottaviano M, et al. Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04466-0
BibTeX
@article{DeFalco2026,
author = {De Falco, Vincenzo and Colloca, Antonino and Argenziano, Giuseppe and Scala, Marcella and Guida, Michele and Ottaviano, Margaret and Sergi, Maria Chiara and Santarpia, Mariacarmela and Del Giudice, Teresa and Grimaldi, Antonio Maria and Cozzolino, Silvana and Forte, Miriam and Caraglia, Francesco and Cioli, Eleonora and Esposito, Alfonso and Giugliano, Maria Cristina and Sparano, Francesca and Iovino, Francesco and Tolone, Salvatore and Docimo, Giovanni and Colella, Giuseppe and Faenza, Mario and Franco, Renato and Scharf, Camila and Russo, Anna and Formisano, Luigi and Ciardiello, Davide and Ascierto, Paolo Antonio and Ciardiello, Fortunato and Troiani, Teresa},
title = {Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {11},
doi = {10.1007/s00262-026-04466-0}
}
EUVIMED